Korean J Intern Med.
2015 Sep;30(5):675-683. 10.3904/kjim.2015.30.5.675.
The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
- Affiliations
-
- 1Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea. hs52silver@gmail.com
- 2Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
- 3Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
- 4Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 5Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- 6Department of Internal Medicine, National Cancer Center, Goyang, Korea.
- 7Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea.
- 8Department of Internal Medicine, Pusan National University Hospital, Busan, Korea.
- 9Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
- 10Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
- 11Department of Hematology and Oncology, Ulsan University Hospital, Ulsan, Korea.
- 12Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.
- 13Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea.
- KMID: 2381566
- DOI: http://doi.org/10.3904/kjim.2015.30.5.675
Abstract
- BACKGROUND/AIMS
The purpose of this study was to determine the correlations between inflammatory factors-including absolute lymphocyte count, lactate dehydrogenase, beta2-microglobulin, albumin, C-reactive protein, and ferritin-and the prognosis for survival in patients with multiple myeloma (MM) treated with induction chemotherapy containing thalidomide and who underwent autologous stem cell transplantation (ASCT).
METHODS
Data from patients at 13 university hospitals in South Korea were collected retrospectively between December 2005 and May 2013.
RESULTS
The median age of the 232 patients was 57 years (range, 33 to 77) and the male to female ratio was 1.09:1. In the multivariate analysis, fewer than two combined abnormal inflammatory factors was the only independent prognostic factor for superior progression-free survival (relative risk [RR], 0.618; 95% confidence interval [CI], 0.409 to 0.933; p = 0.022), and platelet count > 100 x 109/L and fewer than two combined abnormal inflammatory factors were independent prognostic factors for superior overall survival (RR, 4.739; 95% CI, 1.897 to 11.839; p = 0.001 and RR, 0.263; 95% CI, 0.113 to 0.612; p = 0.002, respectively).
CONCLUSIONS
Patients with two or more than two combined inflammatory factors who were treated with thalidomide induction chemotherapy and who underwent ASCT showed significantly shorter survival compared to those with fewer than two combined inflammatory factors. These results could be helpful for predicting prognosis in patients with MM.
Keyword
MeSH Terms
-
Adult
Aged
Antineoplastic Agents/adverse effects/*therapeutic use
Biomarkers, Tumor/*blood
Chemotherapy, Adjuvant
Disease-Free Survival
Female
Hospitals, University
Humans
Induction Chemotherapy
Inflammation Mediators/*blood
Kaplan-Meier Estimate
Male
Middle Aged
Multiple Myeloma/blood/diagnosis/*drug therapy/immunology/mortality
Multivariate Analysis
Neoadjuvant Therapy
Odds Ratio
Proportional Hazards Models
Republic of Korea
Retrospective Studies
Risk Factors
Stem Cell Transplantation
Thalidomide/adverse effects/*therapeutic use
Time Factors
Transplantation, Autologous
Treatment Outcome
Antineoplastic Agents
Biomarkers, Tumor
Inflammation Mediators
Thalidomide
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Cutaneous Plasmacytoma Treated with Thalidomide
- Diagnosis and therapy of multiple myeloma
- A Case of Extramedullary Progression Despite of Serologic Improvement in a Patient Treated with Thalidomide for Multiple Myeloma
- Acute Exacerbation of Chronic Hepatitis B During Thalidomide Therapy for Multiple Myeloma: A Case Report
- Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
